WO2010082219A4 - An arteether injection for treatment of malaria - Google Patents
An arteether injection for treatment of malaria Download PDFInfo
- Publication number
- WO2010082219A4 WO2010082219A4 PCT/IN2009/000757 IN2009000757W WO2010082219A4 WO 2010082219 A4 WO2010082219 A4 WO 2010082219A4 IN 2009000757 W IN2009000757 W IN 2009000757W WO 2010082219 A4 WO2010082219 A4 WO 2010082219A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arteether
- malaria
- treatment
- ethyl
- butylated hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Malaria is a vector borne infectious disease caused by protozoan parasites. Oil based arteether injections are used as anti-malarial drugs, specifically for the treatment of chloroquine resistant Plasmodium falciparum malaria and cerebral malaria cases. Arteether is a fast acting blood schizontocide. The injectable formulation of arteether contains a mixture of ethyl oleate and ethyl alcohol in specific concentrations to reduce the viscosity and the filling volume of the product. This creates minimum muscle pain and muscle stiffness because a higher concentration of arteether (150 mg) is present in a small volume of injectable solution (1 ml). Other pharmaceutical excipients like antioxidants and preservatives are also used in the formulation.
Claims
1. An injectable formulation for the treatment of malaria comprises arteether, ethyl alcohol, benzyl alcohol, butylated hydroxy toluene, butylated hydroxy anisol, propyl gallate and ethyl oleate.
2. The injectable formulation for the treatment of malaria as claimed in claim 1 wherein, each 100 ml of injectable solution contains, 15000 mg arteether, 4-6 ml benzyl alcohol, 10-15 ml ethyl alcohol, 5 mg butylated hydroxy toluene, 3.3 mg butylated hydroxy anisol, 5 mg propyl gallate and ethyl oleate quantity sufficient to make up the volume up to 100 ml .
3. The process of preparing an injectable formulation for the treatment of malaria comprises the following steps:
(a) dissolving arteether in half the quantity of ethyl oleate;
(b) adding benzyl alcohol to the mixture prepared in step (a) and stirring properly; (c) dissolving butylated hydroxy toluene, butylated hydroxy anisol and propyl gallate in ethyl oleate;
(d) adding the mixture of step (c) to the mixture in step (a);
(e) adding ethyl alcohol to the mixture prepared in step (a) in a closed container; (f) adjusting the final volume with ethyl-oleate;
4. The process of preparing an injectable formulation for the treatment of malaria as claimed in claim 5 wherein, nitrogen flushing is done during solution preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AP2011005552A AP2984A (en) | 2009-01-14 | 2009-12-30 | An arteether injection for treatment of malaria |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN97/MUM/2009 | 2009-01-14 | ||
| IN97MU2009 | 2009-01-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2010082219A2 WO2010082219A2 (en) | 2010-07-22 |
| WO2010082219A3 WO2010082219A3 (en) | 2010-11-04 |
| WO2010082219A4 true WO2010082219A4 (en) | 2010-12-23 |
Family
ID=42340178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2009/000757 WO2010082219A2 (en) | 2009-01-14 | 2009-12-30 | An arteether injection for treatment of malaria |
Country Status (2)
| Country | Link |
|---|---|
| AP (1) | AP2984A (en) |
| WO (1) | WO2010082219A2 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000044333A2 (en) * | 1999-01-28 | 2000-08-03 | Dinesh Shantilal Patel | Novel injectable antimalarial compositions of artemisinin |
| WO2004071509A1 (en) * | 2003-02-12 | 2004-08-26 | Nippon Chemiphar Co., Ltd. | Oligodendrocyte differentiation promoters |
| US7989491B2 (en) * | 2003-02-12 | 2011-08-02 | Georgetown University | Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| CN1650854A (en) * | 2004-12-08 | 2005-08-10 | 广州中生生物技术有限公司 | Preparation technology of micro emulsion containing artemisic methyl ether (or artemisic ethyl ether or artemisic succinate) |
-
2009
- 2009-12-30 WO PCT/IN2009/000757 patent/WO2010082219A2/en active Application Filing
- 2009-12-30 AP AP2011005552A patent/AP2984A/en active
Also Published As
| Publication number | Publication date |
|---|---|
| AP2011005552A0 (en) | 2011-02-28 |
| WO2010082219A2 (en) | 2010-07-22 |
| AP2984A (en) | 2014-09-30 |
| WO2010082219A3 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1250220C (en) | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation | |
| CN103906522B (en) | Compositions, dosage forms, and coadministration of opioid agonist compound and analgesic compound | |
| TWI250018B (en) | Highly concentrated stable meloxicam solutions | |
| JP2018203773A (en) | Astaxanthin anti-inflammatory synergistic combinations | |
| CN1668293A (en) | Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer | |
| US20210177845A1 (en) | Pde9 inhibitors for treating sickle cell disease | |
| JP2017513925A (en) | Sustained release buprenorphine solution | |
| US9006215B2 (en) | Pharmaceutical preparation comprising propofol salt and cyclodextrin | |
| US10905685B2 (en) | Intrathecal hydromorphone solutions having improved stability | |
| JP2013538843A (en) | Cyclosporine emulsion | |
| US20180177777A1 (en) | Formulations for mitigating opioid overdose and methods of making and using the same | |
| US9693963B2 (en) | 2,2′,6,6′-tetraisopropyl-4,4′-2-biphenol soft capsule and method for preparing same | |
| WO2010082219A4 (en) | An arteether injection for treatment of malaria | |
| Li et al. | Pharmacokinetic and pharmacodynamic profiles of rapid-acting artemisinins in the antimalarial therapy | |
| US20100120780A1 (en) | Treatments for premature ejaculation in humans | |
| CN1197568C (en) | Dihydroartemisinin preparation for controlling broad-spectrum malaria and its preparation method | |
| US20110071207A1 (en) | Oligomer-Aryloxy-Substituted Propanamine Conjugates | |
| US11382871B2 (en) | Pharmaceutical composition containing curcumin | |
| KR20220106158A (en) | Cannabinoids and Lycopene Anti-inflammatory Synergistic Combination | |
| CN203123076U (en) | Telmisartan/amlodipine tablet | |
| CN105496951A (en) | Preparation method of slow-released enrofloxacin injection | |
| CN114302724A (en) | PDE9 inhibitors for the treatment of sickle cell disease | |
| US20050202050A1 (en) | Single tank process for preparing tannate liquid and semi-solid dosage forms | |
| WO2007132328A3 (en) | Novel galenic forms of artemisin and its derivatives in combination with other antimalarial agents for treating malaria | |
| CN1893892A (en) | Pharmaceutical formulations of camptothecins and process for making same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09838198 Country of ref document: EP Kind code of ref document: A2 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09838198 Country of ref document: EP Kind code of ref document: A2 |